These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
208 related articles for article (PubMed ID: 36379836)
1. Dabrafenib and Trametinib Therapy for Advanced Anaplastic Thyroid Cancer - Real-World Outcomes From UK Centres. Lorimer C; Cheng L; Chandler R; Garcez K; Gill V; Graham K; Grant W; Sardo Infirri S; Wadsley J; Wall L; Webber N; Wong KH; Newbold K Clin Oncol (R Coll Radiol); 2023 Jan; 35(1):e60-e66. PubMed ID: 36379836 [TBL] [Abstract][Full Text] [Related]
2. Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study. Subbiah V; Kreitman RJ; Wainberg ZA; Cho JY; Schellens JHM; Soria JC; Wen PY; Zielinski CC; Cabanillas ME; Boran A; Ilankumaran P; Burgess P; Romero Salas T; Keam B Ann Oncol; 2022 Apr; 33(4):406-415. PubMed ID: 35026411 [TBL] [Abstract][Full Text] [Related]
3. Real-World Experience with Targeted Therapy for the Treatment of Anaplastic Thyroid Carcinoma. Iyer PC; Dadu R; Ferrarotto R; Busaidy NL; Habra MA; Zafereo M; Gross N; Hess KR; Gule-Monroe M; Williams MD; Cabanillas ME Thyroid; 2018 Jan; 28(1):79-87. PubMed ID: 29161986 [TBL] [Abstract][Full Text] [Related]
4. Complete Surgical Resection Following Neoadjuvant Dabrafenib Plus Trametinib in Wang JR; Zafereo ME; Dadu R; Ferrarotto R; Busaidy NL; Lu C; Ahmed S; Gule-Monroe MK; Williams MD; Sturgis EM; Goepfert RP; Gross ND; Lai SY; Gunn GB; Phan J; Rosenthal DI; Fuller CD; Morrison WH; Iyer P; Cabanillas ME Thyroid; 2019 Aug; 29(8):1036-1043. PubMed ID: 31319771 [No Abstract] [Full Text] [Related]
5. Checkpoint Inhibition in Addition to Dabrafenib/Trametinib for BRAF Hamidi S; Iyer PC; Dadu R; Gule-Monroe MK; Maniakas A; Zafereo ME; Wang JR; Busaidy NL; Cabanillas ME Thyroid; 2024 Mar; 34(3):336-346. PubMed ID: 38226606 [No Abstract] [Full Text] [Related]
6. Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer. Subbiah V; Kreitman RJ; Wainberg ZA; Cho JY; Schellens JHM; Soria JC; Wen PY; Zielinski C; Cabanillas ME; Urbanowitz G; Mookerjee B; Wang D; Rangwala F; Keam B J Clin Oncol; 2018 Jan; 36(1):7-13. PubMed ID: 29072975 [TBL] [Abstract][Full Text] [Related]
7. Rechallenge with dabrafenib plus trametinib in anaplastic thyroid cancer: A case report and review of literature. Arıkan R; Telli TA; Demircan NC; Başoğlu T; Ercelep Ö; Atasoy BM; Özgüven S; Dane F; Yumuk PF Curr Probl Cancer; 2021 Apr; 45(2):100668. PubMed ID: 33127167 [TBL] [Abstract][Full Text] [Related]
8. Target therapy for BRAF mutated anaplastic thyroid cancer: a clinical and molecular study. da Silva TN; Rodrigues R; Saramago A; Pires C; Rito M; Horta M; Martins C; Leite V; Cavaco BM Eur J Endocrinol; 2023 Jan; 188(1):. PubMed ID: 36651156 [TBL] [Abstract][Full Text] [Related]
9. Case report: Complete response of an anaplastic thyroid carcinoma patient with Gui L; Zhu Y; Li X; He X; Ma T; Cai Y; Liu S Front Immunol; 2023; 14():1178682. PubMed ID: 37122752 [TBL] [Abstract][Full Text] [Related]
10. A Phase 2 Study of Encorafenib in Combination with Binimetinib in Patients with Metastatic Tahara M; Kiyota N; Imai H; Takahashi S; Nishiyama A; Tamura S; Shimizu Y; Kadowaki S; Ito KI; Toyoshima M; Hirashima Y; Ueno S; Sugitani I Thyroid; 2024 Apr; 34(4):467-476. PubMed ID: 38343359 [No Abstract] [Full Text] [Related]
12. Advances in the management of anaplastic thyroid carcinoma: transforming a life-threatening condition into a potentially treatable disease. Califano I; Smulever A; Jerkovich F; Pitoia F Rev Endocr Metab Disord; 2024 Feb; 25(1):123-147. PubMed ID: 37648897 [TBL] [Abstract][Full Text] [Related]
13. Interstitial lung disease associated with combination therapy of dabrafenib and trametinib in metastatic BRAF Zeng Q; Deng Y; Zhang L; Wang W Int J Clin Pharmacol Ther; 2022 May; 60(5):225-231. PubMed ID: 35072623 [TBL] [Abstract][Full Text] [Related]
14. Salutary Response to Targeted Therapy in Anaplastic Thyroid Cancer. Fazeli S; Paal E; Maxwell JH; Burman KD; Nylen ES; Khosla SG J Investig Med High Impact Case Rep; 2019; 7():2324709619890942. PubMed ID: 31766881 [No Abstract] [Full Text] [Related]
15. [Anaplastic thyroid carcinoma : new therapeutic approaches]. Stamatiou A; Herrera-Gómez RG; Szturz P; Bisig B; Romano E; Sykiotis G; Gorostidi F; La Rosa S; Kopp P; Cristina V Rev Med Suisse; 2021 May; 17(739):962-966. PubMed ID: 34009754 [TBL] [Abstract][Full Text] [Related]
16. Combination Gunda V; Ghosh C; Hu J; Zhang L; Zhang YQ; Shen M; Kebebew E Thyroid; 2023 Oct; 33(10):1201-1214. PubMed ID: 37675898 [No Abstract] [Full Text] [Related]
17. Neoadjuvant treatment with lenvatinib and pembrolizumab in a Barbaro D; Forleo R; Profilo MA; Lapi P; Giani C; Torregrossa L; Macerola E; Materazzi G Front Endocrinol (Lausanne); 2024; 15():1389294. PubMed ID: 39045273 [TBL] [Abstract][Full Text] [Related]
18. Mutation based approaches to the treatment of anaplastic thyroid cancer. McCrary HC; Aoki J; Huang Y; Chadwick B; Kerrigan K; Witt B; Hunt JP; Abraham D Clin Endocrinol (Oxf); 2022 May; 96(5):734-742. PubMed ID: 35067961 [TBL] [Abstract][Full Text] [Related]
19. Effects of dabrafenib and erlotinib combination treatment on anaplastic thyroid carcinoma. Choi YS; Kwon H; You MH; Kim TY; Kim WB; Shong YK; Jeon MJ; Kim WG Endocr Relat Cancer; 2022 May; 29(6):307-319. PubMed ID: 35343921 [TBL] [Abstract][Full Text] [Related]
20. Dabrafenib plus trametinib treatment in patients with anaplastic thyroid carcinoma: an Argentinian experience. Bueno F; Smulever A; Califano I; Guerra J; Del Grecco A; Carrera JM; Giglio R; Rizzo M; Lingua A; Voogd A; Negueruela MDC; Abelleira E; Pitoia F Endocrine; 2023 Apr; 80(1):134-141. PubMed ID: 36617605 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]